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Platelet activation has been implicated in microvascular thrombosis and organ failure in critically ill patients. In the ﬁrst part the
present paper summarises important data on the role of platelets in systemic inﬂammation and sepsis as well as on the beneﬁcial
eﬀects of antiplatelet drugs in animal models of sepsis. In the second part the data of retrospective and prospective observational
clinical studies on the eﬀect of aspirin and other antiplatelet drugs in critically ill patients are reviewed. All of these studies have
shown that aspirin and other antiplatelet drugs may reduce organ failure and mortality in these patients, even in case of high
bleedingrisk.Fromthedatareviewedhereinterventionalprospectivetrialsareneededtotestwhetheraspirinandotherantiplatelet
drugs might oﬀer a novel therapeutic option to prevent organ failure in critically ill patients.
1.PlateletsinSystemicInﬂammationandSepsis
Sepsis and multiple organ failure are leading causes of
death in critically ill patients. There is good evidence that
blood platelets play an important role in the development
of multiple organ failure (MOF) in these patients [1–3].
A decrease in the number of circulating platelets is very
often observed when patients develop sepsis and MOF, and
thrombocytopenia is a powerful predictor of mortality [4–
6]. During systemic inﬂammation and infection platelets
become activated as indicated by an increase in the number
ofCD62P-positiveplateletsandplatelet-leukocyteconjugates
[7–9]. Diﬀerent mechanisms may contribute to platelet
activation, including imbalance between plasma level of high
molecular weight von-Willebrand factor and its cleaving
protease, ADAMTS-13 [10–13], and binding of endotox-
ins to speciﬁc receptors at the platelet surface [14–16].
Adhesion of activated platelets within the microcirculation
and formation of platelet aggregates contributes to vascular
h y p e r p e r m e a b i l i t ya sw e l la sh y p o p e r f u s i o n[ 17–20].
However, platelets do not only contribute to the sepsis-
associated disturbances of haemostasis, but they also signiﬁ-
cantly inﬂuence inﬂammatory processes:
(i) release of compounds with well-known pro- or anti-
inﬂammatory eﬀects such as cytokines, chemokines,
and lipid mediators [21–26],
(ii) activation of the complement system [27, 28],
(iii) release of antibacterial compounds and, together
with neutrophils, trapping of bacteria [25, 29–31],
(iv) receptor-mediated adhesion to monocytes, neu-
trophils, and endothelial cells resulting in changes of
cellular functions such as production of cytokines,
chemokines, and reactive oxygen species as well as
recruitment and immigration of leukocytes at the site
of tissue damage [22, 25, 26, 32].
Insummary,plateletsmaycontributetothedevelopment
of MOF by disturbing blood ﬂow as well as by modulating2 Thrombosis
the systemic inﬂammation. Thus the question arises whether
antiplatelet drugs may have a beneﬁt on the outcome in
critically ill patients, that is, in patients with systemic inﬂam-
mation, severe infections, or sepsis.
2.AntiplateletDrugs
Antiplatelet drugs arewidelyused in patients with cardiovas-
cular disease for the secondary prevention of atherothrom-
botic events [34–36]. The mostly used drug is aspirin which
is an irreversible inhibitor of cyclooxygenase. In platelets as-
pirin inhibits the formation of thromboxane A2 which is a
potentplateletactivator[37,38].Sinceaspirinalsoaﬀectsthe
cyclooxygenase in gastric mucosa which can lead to serious
bleeding, it is used as an inhibitor of platelet function for
the prevention in patients with risk for atherothrombosis in
ratherlowdosage,thatis, ≤325mg/day,andinmanypatients
at dosage lower than 160mg/day [35, 36, 39–42].
Clopidogrel and the more recently developed drugs pra-
sugrel and ticagrelor are rather speciﬁc inhibitors of platelet
function. These drugs or their metabolic products interact
with the platelet ADP receptor P2Y12, and they are used in
combination or instead of aspirin [43–46]. Another group of
antiplatelet agents are inhibitors of the glycoprotein IIb/IIIa
complex on the platelet surface. These agents block the
binding of ﬁbrinogen to the receptor which is essential for
platelet aggregation [47–49].
3. Anti-InﬂammatoryEffects of
AntiplateletDrugsinPatientswith
CardiovascularDiseases
Many studies have shown that aspirin and clopidogrel not
only reduce the risk of atherothrombotic events, but also
reduce markers of systemic inﬂammation including C-
reactive protein, soluble CD62P and CD54, pro-inﬂam-
matory cytokines, and platelet-leukocyte conjugates in these
patients [50–54]. It is assumed that the anti-inﬂammatory
eﬀects of antiplatelet drugs are mediated by an inhibition of
platelet activation [53].
4. AnimalStudies on the Action of Antiplatelet
Drugs in SystemicInﬂammation andSepsis
In the late seventies and in the eighties of the past cen-
tury some studies on the beneﬁcial eﬀect of inhibitors of
prostaglandin and thromboxane synthesis, including aspirin,
onthesurvivalinanimalmodelsofsepsiswerereported[55–
57]. It was shown that aspirin reduced platelet accumulation
in the lung in a mouse model of endotoxinaemia [58, 59].
Other studies investigated the eﬀects of glycoprotein IIb/IIIa
inhibitors. Using monoclonal antibodies, a reduction of
thrombotic microangiopathy and ischemic tissue injury in
various animal models of endotoxinaemia or sepsis could
be shown [60–62]. More recently, the eﬀects of the ADP
receptor antagonist clopidogrel in endotoxinaemia were
tested. Evangelista et al. [63, 64] reported an inhibition
of platelet-dependent leukocyte activation as well as an
inhibition of the production of proinﬂammatory cytokines
in mice after endotoxin administration. Our group could
recently show that in a similar mouse model clopidogrel
prevented endotoxin-induced thrombocytopenia, reduced
ﬁbrin deposition in lung tissue, and inhibited the upreg-
ulation of some genes, known to be involved in inﬂam-
mation, in peripheral blood cells [65]. In a mouse model
of polymicrobial sepsis Seidel et al. [66] demonstrated
that clopidogrel reduced cell damage and liver dysfunction
as indicated by reducing the sepsis-mediated increase in
serum lactate dehydrogenase activity and serum bilirubin
concentration. Using a rat model of endotoxin-induced
systemic inﬂammation Hagiwara et al. [67] reported that
clopidogrel attenuated the increase in serum levels of pro-
inﬂammatory cytokines (TNFα, IL-6 and HMBG1) and the
tissue injury in liver and lung. A beneﬁt of clopidogrel was
also shown in a rat model of chronic kidney disease [68].
5. Beneﬁt of AspirinandOther Antiplatelet
DrugsinCriticallyIllPatients
Based on the evidence that platelets play an important role
in the development of organ failure in critically ill patients
weperformedthreeretrospectiveclinicalstudies.Ascritically
ill patients are often elderly people we assumed that some
of them might be on antiplatelet drugs for the prevention
of thromboembolic events due to cardiovascular diseases.
Indeed, 20–25% of the patients who were included in the
analysis had a preexisting medication with aspirin or/and
clopidogrel [33, 65]. Even if the administration of aspirin
and/or clopidogrel was discontinued during the stay in
hospital, inhibition of platelet function should persist for
about one week [69, 70].
5.1. Patients Admitted to Hospital with Community Acquired
Pneumonia. In a ﬁrst study we analysed data from patients
who were admitted to the hospital for community acquired
pneumonia (CAP). Since statins are discussed to improve
the outcome in critically ill patients [71–76], patients with
prehospital use of statins were excluded from the study.
Two hundred twenty-four patients were enrolled and 38 of
them had a preexisting medication with aspirin and 8 were
on clopidogrel or ticlopidin for at least 6 month prior to
admissiontohospital[65].Asendpointsofthestudyweused
the length of stay in the hospital, and the admission to the
intensive care unit (ICU) as an indicator of organ failure.
Despite the fact that patients on antiplatelet drugs were
about 12 years older when compared to those without such
preexisting medication, they were less frequently admitted
to ICU (9.1% versus 26.3%). This diﬀerence was more
pronounced when age-matched subgroups were compared:
24.4% of patients without and only 5.0% of patients with
antiplatelet drugs required ICU treatment. In the age-
matched subgroups we observed also a signiﬁcant shorter
stay in hospital for the patients on antiplatelet drugs (13.9
± 6.2 versus 18.2 ± 10.2 days). The beneﬁcial eﬀect of
the preexisting medication with antiplatelet drugs was also
obvious when stepwise logistic regression analysis was usedThrombosis 3
Internal medicine
Surgery
Medical
departments:
Type of
treatment: Surgical
All
Trauma: Craniocerebral
ISS > 16
All
Active
bleeding:
Intracranial
Need of transfusion
0 0.2 0.4 0.6 0.8 1
Odds ratio
Allocation to
Figure 1: The ﬁgure summarises the eﬀect of antiplatelet drugs (aspirin or/and clopidogrel) in patients admitted to an ICU as reported by
Winning et al. [33]. Odds ratios for ICU mortality with 95% conﬁdence intervals were calculated by stepwise logistic regression with age,
gender, APACHE II score, and preexisting medication with antiplatelet drugs as independent variables.
tocalculatetheoddsratiofortheneedofICUtreatment.The
following variables were included as independent variables:
SOFA (sepsis-related organ failure assessment) score, plasma
level of C-reactive protein, platelet and leukocyte counts
(all measured at day of admission), age, gender, and the
preexisting medication with antiplatelet drugs. Odds ratio
of 0.32 (95% conﬁdence interval: 0.10–1.00) for all patients
and 0.19 (0.04–0.87) for the age-matched subgroup were
obtained, indicating a marked reduction in organ failure by
antiplatelet drugs [65].
5.2. Patients Admitted to an Intensive Care Unit. In a second
study we analysed the data from 615 patients who were
admitted to the intensive care unit (ICU) within 24 hours
after arrival in hospital. From these patients 21% had
a preexisting medication with aspirin (≤160mg/d), and
4% were on clopidogrel or a combination of aspirin and
clopidogrel. Patients on statins were excluded [33]. Patients
were allocated to internal medicine as well as various surgery
departments (general surgery, trauma surgery, neurosurgery,
and gynaecology). Patients with and without antiplatelet
drugs did not only diﬀer in age (median: 72 versus 56
years), but also in the severity of their illness as measured
by the APACHE (Acute Physiology and Chronic Health
Evaluation) II score at the day of ICU admission (25 versus
19). Despite these marked diﬀerences in age and APACHE
II score which are established risk factors of MOF, there was
no diﬀerence in ICU mortality as clinical end point of the
study. Stepwise logistic regression with APACHE II score,
age, gender, and use of antiplatelet drugs indicated that in
addition to age and APACHE II score the use of antiplatelet
drugs had a highly signiﬁcant impact on mortality. The
calculated odds ratios amounted for age 1.04 (1.03–1.06),
for APACHE II 1.16 (1.12–1.19), and for antiplatelet drugs
0.19 (0.12–0.33). That means that the prehospital use of
antiplateletdrugswouldreducemortalitybyafactorofabout
5[ 33].
Figure 1 illustrates the eﬀects of antiplatelet drugs on
subgroups of patients [33]. Surprisingly, in patients who
were allocated to surgical departments, the preexisting
medication with antiplatelet drugs was associated with a
slightly better outcome when compared to those patients
allocated to internal medicine department. In neurosurgery
patients(46withand196withoutantiplateletdrugs)anodds
ratio for mortality of 0.12 (0.04–0.30) was calculated. In
contrast, patients allocated to trauma surgery did not show
any beneﬁt from antiplatelet drugs (odds ratio = 0.92 (0.06–
13.6)) [33]. However, in the subgroup of trauma patients (22
with and 159 without antiplatelet drugs) antiplatelet drugs
seemed to exert an enormous beneﬁt as an odds ratio as low
as 0.06 (0.01–0.35) was calculated. This was true for patients
withmultipletrauma(injuryseverityscore>16)aswellasfor
patientswithcraniocerebraltrauma(Figure 1).Evenpatients
with active bleeding including those who needed transfusion
or presented intracranial bleeding seemed to proﬁt from
the preexisting medication with antiplatelet drugs. Finally
there was no marked diﬀerence in the beneﬁcial eﬀect of
antiplatelet drugs between patients who received medical
treatmentandthosewithsurgicaltreatment(Figure 1). Thus
bleeding and/or high risk for bleeding seemed not to abolish
or reverse the calculated beneﬁt of antiplatelet drugs in the
critically ill patients. However, one should consider the data
obtained by the stepwise logistic regression analysis in some
of the subgroups of patients with some caution as (i) the
numbers of patients were sometimes rather low and (ii)
patients without antiplatelet drugs were much younger (up
to 30 years) when compared to those with such medication.
Therefore we reevaluated the subgroups in a cohort of
APACHE II score and age-matched patients using 2 × 2t a b l e
analysis [33]. Under this condition the beneﬁcial eﬀect of4 Thrombosis
Table 1: Age, gender, APACHE II score, and mortality in a
subgroup of patients with and without an exclusive prehospital
aspirin medication. The data were taken from Winning et al. [33].
Control ASA Signiﬁcance
Number 461 129
Age (years) 52.2 ± 20.4 69.1 ± 9.3 P<0.00001
Male/female
(%) 56.8/43.2 57.4/42.6 n.s.
APACHE II 19.4 ± 8.5 26.1 ± 9.3 P<0.00001
Mortality
(%)∗ 38.4 38.8 n.s.
Data are given as mean ± standard deviation (sd), total numbers or %.
Signiﬁcances were calculated either by t-test for unpaired samples or by 2 ×
2 table analysis. n.s. = not signiﬁcant. ∗ ICU mortality.
Table 2: Eﬀect of aspirin on outcome of critically ill patients
characterised in Table 1. Odds ratios for ICU mortality were
calculated using data from our recently published study [33]. The
modelofstepwiselogisticregressionincludedage,gender,APACHE
II score, and preexisting medication with aspirin as independent
variables.
Variable Odds ratio (95% CI)
Age 1.04 (1.03–1.06)
APACHE II score 1.16 (1.13–1.20)
Aspirin 0.20 (0.12–0.35)
antiplatelet drugs in patients with active bleeding or a high
bleeding risk was no longer signiﬁcant, but the calculated
odds ratios for mortality were in most of the subgroups in
a range of 0.42 to 0.88. There were only two exceptions:
in patients allocated to the trauma surgery department an
odds ratio of 3.67 (0.38–42.2) was calculated. In contrast,
a signiﬁcant beneﬁt on outcome was still obtained for
neurosurgery patients (odds ratio = 0.32 (0.12–0.84)) [33].
For the present paper we have reevaluated our previously
reported data [33] summarised above. We analysed the data
of those patients who had a preexisting medication with only
low-dose aspirin, and we excluded those patients who had
clopidogrel or a combination of aspirin and clopidogrel. As
for the entire group of patients with antiplatelet drugs we
also found for the “only aspirin” subgroup large diﬀerences
in age and APACHE II score when compared to patients
without antiplatelet drugs. And again, there was no diﬀer-
ence in mortality (Table 1). However using stepwise logistic
regression analysis with mortality as dependent variable
and age, APACHE II score, gender, and preexisting aspirin
medication, we found that aspirin reduced the mortality by
about 80% as indicated by an odds ratio of 0.20 (Table 2).
Thus the calculated beneﬁt of aspirin was in the same range
as calculated for the entire group of patients with aspirin
and/or clopidogrel as shown in Figure 1 and previously
reported [33].
5.3. ICU Patients Presenting Severe Sepsis or Septic Shock. In
a third, not yet published study, we analysed the clinical
recordsof834patientswhowereadmittedtoICUwithsevere
Table 3: Age, APACHE II score, and mortality in patients admitted
toICUwithseveresepsisorsepticshockandwithorwithoutaspirin
medication during ICU stay.
Variable
Aspirin during ICU stay
Signiﬁcance
No Yes
Number 647 187
Age (years) 63.4 ± 14.0 67.9 ± 12.9 P<0.0001
APACHE II 22.6 ± 9.2 24.1 ± 8.3 P<0.05
Mortality (%) 33.8 23.5 P<0.01
Table 4: Eﬀect of ICU aspirin medication on outcome (odds ratio
of mortality∗) of patients with severe sepsis or septic shock. The
modelofstepwiselogisticregressionincludedage,APACHEIIscore
and ICU medication with aspirin as independent variables. ∗ICU
mortality.
Variable Odds ratio (95% CI)
APACHE II score 1.05 (1.03–1.07)
Aspirin 0.55 (0.38–0.81)
sepsis or septic shock. About 20% of these patients received
low-dose aspirin (Table 3). Exclusion criteria were the
administration of other antiplatelet drugs (i.e., clopidogrel)
or nonsteroidal anti-inﬂammatory drugs such as ibuprofen,
diclofenacorindomethacin.AsshowninTable 3,patientson
aspirin were about 4.5 years older and presented a slightly
higherAPACHEIIscoreatthedayofICUadmission.Despite
the diﬀerences in these both risk factors, ICU mortality was
about one third lower in patients receiving aspirin when
compared to those without such medication (Table 3).
Whencalculatingtheoddsratioformortalitybystepwise
logistic regression with age, APACHE II score, and aspirin
medication during ICU stay, we found a reduction in ICU
mortality by aspirin of about 45% (Table 4).
5.4. Patients at Risk for Acute Lung Injury/Acute Respiratory
Distress Syndrome. In June 2011 O’Neal et al. [73] published
the data of a prospective study on the eﬀects of the pre-
hospital use of statins on the prevalence of severe sepsis
and acute lung injury/acute respiratory distress syndrome
(ALI/ARDS) in critically ill patients. The authors included
575 patients admitted to surgical or medical ICU. Exclusion
criteria were admission to trauma or cardiovascular ICU,
primary cardiac diagnoses, and age <40 years. From these
patients 26% were on prehospital statins. Logistic regression
analysis with age, gender, tobacco use, race, APACHE II
score, statin use, and aspirin use indicated that patients on
statin but not those on aspirin were less likely to have or
to develop severe sepsis (odds ratio 0.62, 95% conﬁdence
interval 0.40–0.96) or ALI/ARDS (odds ratio 0.60, 95%
conﬁdence interval 0.36–0.99) during the ﬁrst four days
after ICU admission. Interestingly, the beneﬁt of prehospital
statins may be potentiated by prehospital aspirin. Patients
with both prehospital statins and aspirin had the lowest rateThrombosis 5
of severe sepsis or ALI/ARDS when compared to those with
statins alone or those without statins [73].
The association of prehospital aspirin therapy and
ALI/ARDS was also investigated by Erlich et al. [77]a n d
published in February 2011. The authors evaluated med-
ical records of 161 patients with at least one major risk
factor for ALI/ARDS but who did not meet criteria for
ALI/ARDS at time of hospitalisation. Seventy-nine (49%)
of the patients were on aspirin at hospital admission and
33 (21%) developed ALI/ARDS. Aspirin therapy was asso-
ciated with a signiﬁcantly lower rate of ALI/ARDS when
compared to patients without aspirin (17.7% versus 28.0%;
odds ratio 0.37, 95% conﬁdence interval 0.16–0.84). The
authorsreported thatthebeneﬁtofaspirin therapyremained
signiﬁcant after adjusting for various confounding variables
[77]. A few months later the same group reported the results
of a large multicenter international observational study on
the association of prehospital aspirin therapy and ALI/ARDS
[78]. Inclusion criteria were again at least on risk factor of
ALI (aspiration, pneumonia, sepsis, shock, pancreatitis,
high-risk trauma, or high risk surgery) and age >18 years.
Patients with elective surgery were excluded. A total of
3855 patients were enrolled in the study. Twenty-ﬁve % of
them were receiving aspirin at the time of hospitalisation
and 6.2% developed ALI/ARDS. Patients with aspirin were
signiﬁcantly older (median and interquartile ranges: 70 (59–
81) versus 51 (38–66) years) and had higher APACHE
II scores (12 (8–16) versus 9 (5–14)). Univariate analysis
indicated a reduced incidence of ALI/ARDS in patients with
aspirin (odds ratio 0.65, 95% conﬁdence interval 0.46–0.90).
However this association was attenuated after adjusting for
the propensity to receive aspirin therapy. An odds ratio
(Cochran-Mantel-Haenszelpooledoddsratio)of0.70(0.48–
1.03)wascalculatedinastratiﬁedanalysisbasedondecilesof
the American Society of Anesthesiologists propensity scores
[78].
6. Discussion
Animal studies and observational clinical studies reviewed
here have provided some evidence that antiplatelet drugs
may reduce organ failure and mortality in critically ill
patients. In the clinical studies mostly or exclusively aspirin
was used as the antiplatelet drug, whereas clopidogrel or
GPIIb/IIIa inhibitors as rather speciﬁc antiplatelet drugs
were predominantly used in animal models [60–68]. The
beneﬁt of clopidogrel and GPIIb/IIIa inhibitors in animal
models and the beneﬁt of low-dose aspirin in the observa-
tional clinical studies may indicate that the beneﬁt of aspirin
is indeed mediated by its eﬀect on platelets. However, one
cannot exclude the possibility that the beneﬁt of antiplatelet
drugs, including aspirin, is at least partially due to the
underlyingatheroscleroticvasculardisease.Itiswellaccepted
that atherosclerosis is based on a chronic low-grade systemic
inﬂammation as indicated by moderately increased levels
of markers of inﬂammation, that is, cytokines, C-reactive
protein, or ﬁbrinogen [79–82]. It would be interesting to test
the hypothesis that patients with chronic low-grade systemic
inﬂammation have a decreased prevalence of severe sepsis
and organ failure.
The use of antiplatelet drugs in critically ill patients
seems not to be associated with unfavourable bleeding. A
beneﬁt of antiplatelet drugs was also evident in patients with
an increased bleeding risk such as neurosurgery patients
and not necessarily associated with high blood loss or
worse neurological outcome [33]. This observation is in line
with the recommendation of perioperative continuation of
antiplatelet therapy in patients with high risk of cardio- and
cerebrovascular events [83–86].
7. Conclusion
The data reviewed in the present paper may indicate that
low-dose aspirin, as it is used in patients with cardiovascular,
cerebrovascular, or peripheral vascular diseases, might oﬀer
a novel therapeutic option to prevent organ failure. This
hypothesis warrants testing in prospective interventional
trials.
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